sprodiamide

Known as: Dy-DTPA-BMA, dysprosium DTPA-bis(methylamide), dysprosium diethylenetriaminepentaacetic acid-bis(methylamide) 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2008
01219932008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
PURPOSE To provide evidence that vascular endothelial growth factor (VEGF) genes delivered transendocardially with magnetic… (More)
Is this relevant?
2006
2006
PURPOSE To use (a) dysprosium-based contrast agent (sprodiamide) to confirm the site of myocardial injection and (b) T1-enhancing… (More)
Is this relevant?
2001
2001
PURPOSE To demonstrate the involvement of the various renal structures in acute tubular necrosis (ATN). MATERIAL AND METHODS In… (More)
Is this relevant?
2000
2000
OBJECTIVE To assess the effects of Dy-DTPA-BMA (sprodiamide) on ex-vivo MR imaging of reperfused acute myocardial infarction… (More)
Is this relevant?
1999
1999
The aim of this study was to determine whether the use of a magnetic resonance (MR) susceptibility contrast medium, dysprosium… (More)
Is this relevant?
1997
1997
The purpose of this study was to investigate the dependence of contrast-to-noise ratio (CNR) on the dose and rate of sprodiamide… (More)
Is this relevant?
1996
1996
Fast magnetic resonance (MR) imaging techniques have the capability of demonstrating regions of ischemia caused by stenosis. The… (More)
Is this relevant?
1996
1996
Dynamic magnetic resonance (MR) imaging with contrast agents is a very promising technique for studying tissue perfusion in vivo… (More)
Is this relevant?
1995
1995
The purpose of this study was (1) to monitor the dynamic effects of T1-enhancing and magnetic susceptibility contrast material on… (More)
Is this relevant?
1993
1993
Sprodiamide Injection (S-043 Injection, Nycomed Salutar; WIN 59080, Sterling Winthrop) is a magnetic susceptibility-based MRI… (More)
Is this relevant?